Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Ardelyx, Inc.
< Previous
1
2
Next >
Ardelyx to Participate at the Jefferies London Healthcare Conference
November 10, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
November 06, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
November 03, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
October 31, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
October 30, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
October 23, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023
October 18, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Announces Amendment of Debt Financing Agreement with SLR Capital Partners to Provide $50 Million of Additional Committed Capital
October 17, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
FDA Approves XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor
October 17, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Present Data Updates for XPHOZAH (tenapanor) for Hyperphosphatemia at Kidney Week 2023 November 1-5 in Philadelphia, PA
October 13, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Shares Preliminary Data on Use of IBSRELA® (tenapanor) in Pediatric IBS-C Patients at NASPGHAN 2023
October 04, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
September 28, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Tenapanor for Hyperphosphatemia Approved in Japan
September 25, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Showcased Encouraging Data on Treatment Satisfaction and Efficacy of IBSRELA® (tenapanor) for IBS-C at GHAPP 2023
September 11, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 08, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
September 07, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Reports Second Quarter 2023 Financial Results and Provides 2023 IBSRELA Net Sales Revenue Guidance
August 02, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
July 27, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Report Second Quarter 2023 Financial Results on August 2, 2023
July 26, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Present at the H.C. Wainwright 2nd Annual Kidney Conference
July 20, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Announces Acceptance of New Drug Application for Tenapanor for Hyperphosphatemia in China
July 13, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
June 29, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Leading Proxy Advisory Firms ISS and Glass Lewis Recommend Ardelyx Stockholders Vote in Favor of Proposed Share Increase
June 05, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx to Present at the Jefferies 2023 Healthcare Conference
May 31, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
May 23, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)
May 17, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx, Inc. Reports Employment Inducement Grants
May 15, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 09, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
Ardelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week Conference
May 01, 2023
From
Ardelyx, Inc.
Via
GlobeNewswire
Tickers
ARDX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.